Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3817-3820

  Neri, B ^a,e   Barbagli, G ^b   Bellesi, P ^b   Di Loro, R ^b   Lombardi, V ^c   Lombardo, C ^c   Magrini, T ^c   Mottola, A ^b   Nicita, G ^b   Palminteri, E ^b   Ponchietti, R ^b   Raugei, A ^b   Intini, C ^d  

^a Oncological Day Hospital

^b UNIVERSITY OF FLORENCE   (Italy)

^c Reg Hosp S Giovanni di Dio USL

^d PFIZER INC   (United States)

^e Oncological Day Hospital   (Italy)

Author keywords

Chemotherapy; Epidoxorubicin; Hormone resistance; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

ANDROGEN; CYTOTOXIC AGENT; EPIRUBICIN; GONADORELIN AGONIST; HORMONE;

ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PAIN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 17644449061     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Boyle P: Prostate Cancer 2000: evolution of an epidemic of unknown origin, In: Prostate Cancer 2000 Denis L. Ed Springer Verlag, Heidelberg, 1994.
2. Jensen OM, Esteve J, Moller H, Renard H: Cancer in the European Community and its Member States. Eur J Cancer 26: 1167-1265, 1990.
3. Boyle P, Maisonneuve P, Evstfeeva T, Alexander FE: What is the Significance of Trends in Prostate Cancer? Proceedings 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Paris 1994, pp. 51-65.
4. Leighton J, Clark J, Giantonio B, Ozols R, Hudes G: Genitourinary malignancy. In: "Cancer Chemotherapy and Biological Response Modifiers". Pinedo HM, Longo DL, Chabner BA Eds. Elsevier Science. Amsterdam 1996, pp: 524-563.
5. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation as studies in the Dunning R-3327 H adenocarcinoma. Cancer Res 41: 5070-5075, 1981.
6. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 3: 827-841, 1985.
7. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML: Expression of protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
8. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
9. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: bcl-2 in an inner mitochondrial membrane protein that blocks programmed cell dealh. Nature 348: 334-337, 1990.
10. Hsu B, Marin MC, Brisbay S, McConnell K, McDonnell TJ: Expression of bcl-2 confers multidrug resistance to chemotherapyinduced cell death. Cancer Bull 46: 125-129, 1994.
11. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, McDonnell TJ: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93: 147-155, 1995.
12. Torti FM, Lum BL: Chemotherapy in prostate cancer. In Genitourinary Cancer. Contemporary Issues in Clinical Oncology. Garnick MB Ed. Churchill Livingstone. New York 1985, vol 5.
13. Chan D, Bruzek DJ, Oesterling JE: Prostate specific antigen as a marker for prostate cancer: A monoclonal and polyclonal immunoassay compared. Clin Chem 33: 1916-1920, 1987.
14. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents. In: Evaluation of Chemotherapeutic Agents. McLeod Ed. New York, Columbia University Press, pp 191-205, 1949.
15. Miller AB, Hoogastraten B, Staquet M, Wikler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
16. Crawford ED, Eisenberger MA, McLeod DG et al: A controlled trial of leuporide with and without flutamide in prostatic carcinoma. N Eng J Med 321: 419-423, 1989.
17. Isaacs JT: Cellular factors in the development of resistance to hormonal therapy. In: Drug and Hormone Resistance in Neoplasia. Bruchovsky N, Goldie J Eds CRC Press, Boca Raton, 1981.
18. Isaacs JT: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 117, 1984.
19. Torti FM, Aston D, Lum LB, Kohler M, Williams R, Spaulding JT, Shortliffe L, Freiha FS: Weekly Doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1(8): 477-482, 1983.
20. Brausi M, Jones WG, Fossa SD, de Mulder PHM, Droz JP Lentz MA, van Glabbeke M, Pawinski A: High dose Epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC genitorianry group. Eur J Cancer 31: 1622-1626, 1995.
21. Raghavan D: Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to testing of new drugs. Semin Oncol 15: 371-389, 1990.